Free shipping on all orders over $ 500

Erlotinib Hydrochloride

Cat. No. M1705
Erlotinib Hydrochloride Structure
Synonym:

Tarceva, CP-358774, OSI-774, NSC-718781

Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
50mg USD 38  USD38 In stock
100mg USD 50  USD50 In stock
500mg USD 80  USD80 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Erlotinib Hydrochloride also known as Tarceva, CP-358774, OSI-774 and NSC-718781, is an inhibitor of human EGFR tyrosine kinase (IC50 = 2 nM) and decreases EGFR autophosphorylation in tumor cells (IC50 = 20 nM). Erlotinib specifically targets the epidermal growth factor receptor (EGFR) tyrosine kinase, which is highly expressed and occasionally mutated in various forms of cancer. It binds in a reversible fashion to the adenosine triphosphate (ATP) binding site of the receptor.

Customer Product Validations & Biological Datas
Source Biochem Biophys Res Commun (2015). Figure 3. Erlotinib Hydrochloride
Method Western blot
Cell Lines Female BALB/c nude mice
Concentrations 5 mg/kg
Incubation Time 24 h
Results Erlotinib exerts its anti-tumor effect by inhibiting the intracellular phosphorylation of tyrosine kinase which is related to EGFR. We investigated whether the administration time can affect the ability of erlotinib to inhibit the phosphorylation of EGFR. Under non-drugged state, the phosphorylation of EGFR showed obvious oscillation (p < 0.05, Fig. 3A).
Source Biochem Biophys Res Commun (2015). Figure 2. Erlotinib Hydrochloride
Method Histopathological analysis
Cell Lines Female BALB/c nude mice
Concentrations 5 mg/kg
Incubation Time 21 d
Results Large areas of cystic degeneration and inflammatory infiltration can be easily spotted in the tumor tissue of mice given erlotinib at 08:00, 12:00 and 04:00, and the tumor cells arranged irregularly with necrosis and minimal bleeding.
Protocol (for reference only)
Cell Experiment
Cell lines BxPC-3 and MIAPaCa cells
Preparation method Cell Viability Assay To test the viability of cells treated with B-DIM, erlotinib, or the combination, BxPC-3 and MIAPaCa cells were plated (3,000-5,000 per well) in a 96-well plate and incubated overnight at 37jC. We initially tested a range of concentrations for both B-DIM (10-50 µmol/L) and erlotinib (1-5 µmol/L). Based on the initial results, the concentration of B-DIM (20 Amol/L) and erlotinib (2 Amol/L) were chosen for all assays. The effects of B-DIM (20 µmol/L), erlotinib (2 µmol/L), and the combination on BxPC-3 and MIAPaCa cells were determined by the standard 3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay after 72 h and was repeated three times. The color intensity was measured by a Tecan microplate fluorometer at 595 nm. DMSO-treated cells were considered to be the untreated control and assigned a value of 100%.
Concentrations 1-5 µmol/L
Incubation time 72 h
Animal Experiment
Animal models SCID mice bearing orthotopically implanted BxPC-3 pancreatic tumor cells
Formulation not mentioned
Dosages 50 mg/kg body weight every day for 15 days
Administration i.p.
Chemical Information
Molecular Weight 429.90
Formula C22H23N3O4.HCl
CAS Number 183319-69-9
Solubility (25°C) DMSO 3 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Wang et al. Exp Ther Med. Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in BXPC-3 and PANC-1 human pancreatic cancer cells.

[2] Giovannetti et al. Curr Pharm Des. Molecular mechanisms and modulation of key pathways underlying the synergistic interaction of sorafenib with erlotinib in non-small-cell-lung cancer (NSCLC) cells.

[3] Yeung et al. Expert Rev Pharmacoecon Outcomes Res. Clinical and economic review of erlotinib in non-small-cell lung cancer.

[4] Wu et al. Exp Ther Med. Erlotinib has better efficacy than gefitinib in adenocarcinoma patients without EGFR-activating mutations, but similar efficacy in patients with EGFR-activating mutations.

[5] Weaver et al. Cancer Res. Temporal molecular and biological assessment of an erlotinib-resistant lung adenocarcinoma model reveals markers of tumor progression and treatment response.

Related EGFR/HER2 Products
BBT-207

BBT-207 is a reversible, mutant-specific EGFR inhibitor with antitumor activity.

VRN-11

VRN-11 is an EGFR C797S inhibitor.

TRX-221

TRX-221 is an EGFR C797S inhibitor.

TAS-3351

TAS-3351 is an EGFR C797S inhibitor.

Larotinib mesylate hydrate

Larotinib mesylate hydrate is a potent, broad-spectrum, orally active tyrosine kinase inhibitor (TKI) that primarily targets EGFR with an IC50 of 0.6 nM.

  Catalog
Abmole Inhibitor Catalog




Keywords: Erlotinib Hydrochloride, Tarceva, CP-358774, OSI-774, NSC-718781 supplier, EGFR/HER2, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.